Chronic inflammation drives the development of various cancers, including those of the skin, colon and pancreas. Investigators at Massachusetts General Hospital (MGH) who previously demonstrated high expression levels of an immune molecule called interleukin-33 (IL-33) during cancer-promoting inflammation have now uncovered the details behind the molecule’s effects. The research, which is published in The EMBO Journal, could lead to new strategies to prevent certain cancers.